<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941003-0-00071</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> 5. Section 314.70 is amended by adding new paragraph (f) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.70  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Supplements and other changes to an approved application.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (f)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Claimed exclusivity.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If an applicant claims exclusivity under &sect;314.108 upon approval of a supplemental application for a change to its previously approved drug product, the applicant shall include with its supplemental application the information required under &sect;314.50(j).  <!-- PJG 0012 frnewline --> 6. Section 314.94 is amended by adding a new paragraph (a)(12) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.94  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Content and format of an abbreviated application.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;*  <!-- PJG 0012 frnewline --> (12)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patent certification_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patents claiming drug, drug product, or method of use.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (A) Except as provided in paragraph (a)(12)(iv) of this section, a certification with respect to each patent issued by the United States Patent and Trademark Office that, in the opinion of the applicant and to the best of its knowledge, claims the reference listed drug or that claims a use of such listed drug for which the applicant is seeking approval under section 505(j) of the act and for which information is required to be filed under section 505(b) and (c) of the act and &sect;314.53. For each such patent, the applicant shall provide the patent number and certify, in its opinion and to the best of its knowledge, one of the following circumstances:  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent information has not been submitted to FDA. The applicant shall entitle such a certification ``Paragraph I Certification'';  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent has expired. The applicant shall entitle such a certification ``Paragraph II Certification'';  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) The date on which the patent will expire. The applicant shall entitle such a certification ``Paragraph III Certification''; or  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the abbreviated application is submitted. The applicant shall entitle such a certification ``Paragraph IV Certification''. This certification shall be submitted in the following form:  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> I, ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> name of applicant <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ), certify that Patent No.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=7 f=2 --> XXXXXX <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ) ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> name of proposed drug product <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ) for which this application is submitted.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=10 g=1 f=1 --> The certification shall be accompanied by a statement that the applicant will comply with the requirements under &sect;314.95(a) with respect to providing a notice to each owner of the patent or their representatives and to the holder of the approved application for the listed drug, and with the requirements under &sect;314.95(c) with respect to the content of the notice.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (B) If the abbreviated new drug application refers to a listed drug that is itself a licensed generic product of a patented drug first approved under section 505(b) of the act, the appropriate patent certification under paragraph (a)(12)(i) of this section with respect to each patent that claims the first-approved patented drug or that claims a use for such drug.  <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> No relevant patents.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If, in the opinion of the applicant and to the best of its knowledge, there are no patents described in paragraph (a)(12)(i) of this section, a certification in the following form:  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> In the opinion and to the best knowledge of ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> name of applicant <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ), there are no patents that claim the listed drug referred to in this application or that claim a use of the listed drug.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Method of use patent.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (A) If patent information is submitted under section 505(b) or (c) of the act and &sect;314.53 for a patent claiming a method of using the listed drug, and the labeling for the drug product for which the applicant is seeking approval does not include any indications that are covered by the use patent, a statement explaining that the method of use patent does not claim any of the proposed indications.  <!-- PJG 0012 frnewline --> (B) If the labeling of the drug product for which the applicant is seeking approval includes an indication that, according to the patent information submitted under section 505(b) or (c) of the act and &sect;314.53 or in the opinion of the applicant, is claimed by a use patent, an applicable certification under paragraph (a)(12)(i) of this section.  <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Method of manufacturing patent.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> An applicant is not required to make a certification with respect to any patent that claims only a method of manufacturing the listed drug.  <!-- PJG 0012 frnewline --> (v)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Licensing agreements.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If the abbreviated new drug application is for a drug or method of using a drug claimed by a patent and the applicant has a licensing agreement with the patent owner, a certification under paragraph (a)(12)(i)(A)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) of this section (``Paragraph IV Certification'') as to that patent and a statement that it has been granted a patent license.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            